Definitive Contract HHSO100201500001C
Award Date
10/14/14
Potential Completion Date
11/30/16
Potential Value
$7.5M
Awardee
Profectus Biosciences, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Baltimore, MD 21224, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Cost Plus Fixed Fee contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Profectus Biosciences, Inc., a small business. The contract, with a potential value of $3,383,522.51, is for research and development in the biomedical field, specifically focused on applied research and exploratory development of vaccine technologies. The contract does not have a set-aside designation....
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Profectus Biosciences, Inc., a small business. The contract, valued at $4,214,664.98, is for the production of a pDNA vaccine expressing FLSC as part of the agency's Staged Vaccine Development program. The contract does not have a set-aside designation. The contract supports the development of novel vaccine...
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Profectus Biosciences, Inc., a small business concern, for the development of novel vaccine technologies and strategies. The contract has a total potential value of $322,336.00 and was awarded under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed...
<p>This is a $81,976,383.00 definitive, cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Public Health Vaccines LLC, a self-certified small disadvantaged business, for the advanced research and development of an RVSV-MARV vaccine. The contract has an ultimate completion date of August 31, 2027 and was awarded on February 1, 2019. The contract does not have a set-aside designation.</p>
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
This is a $78,531,649 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Merck Sharp & Dohme LLC (doing business as Merck) to advance the development of the V920 Ebola vaccine using a recombinant vesicular stomatitis virus vector. The contract has an ultimate completion date of September 30, 2024 and does not have a set-aside designation. Merck is a major pharmaceutical manufacturer and supplier to the...
This is a $93,164,303.39 cost plus fixed fee definitive contract awarded by the U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response, to Janssen Vaccines & Prevention B.V. (JPC), a foreign-owned for-profit organization, on September 14, 2015. The contract has an ultimate completion date of August 16, 2024 and is not set-aside. The contract is for products and services related to HHS's preparedness and response programs, though...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Battelle Memorial Institute, a nonprofit research and development organization. The $5,638,781.12 cost-plus-award-fee contract supports the evaluation of Ebola virus and other filovirus vaccines in a novel ferret model. This work is part of the NIAID's broader efforts to develop medical countermeasures against...
This is a $111,268,952.26 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Merck Sharp & Dohme LLC (doing business as Merck), a for-profit pharmaceutical manufacturer. The contract is for the manufacturing and development of the RVSV-ZEBOV vaccine, a critical medical countermeasure. It does not have a set-aside designation. Merck also holds several significant indefinite delivery vehicles...